Literature DB >> 22473010

The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies.

I-Fan Wang1, Hsiang-Yu Chang, Shin-Chen Hou, Gunn-Guang Liou, Tzong-Der Way, C-K James Shen.   

Abstract

The degraded, misfolded C terminus of TAR DNA-binding protein-43 is associated with a wide spectrum of neurodegenerative diseases, particularly frontotemporal lobar degeneration with ubiquitin-positive inclusions and amyotrophic lateral sclerosis. However, the precise mechanism of pathological cleavage of the TAR DNA-binding protein-43 remains unknown. Here we show that the TAR DNA-binding protein-43 C-terminal protein physically interacts with itself or with the cellular-folded yeast prion domain of Sup35 forming dynamic aggregates. This prion-like nature governs known cellular functions of the TAR DNA-binding protein-43, including subcellular localisation and exon skipping of the cystic fibrosis transmembrane conductance regulator. Significantly, mutants with a failure to engage in prion-like interactions are processed into an ~24-kDa C-terminal fragment of the TAR DNA-binding protein-43. The estimated cleavage site of degraded TAR DNA-binding protein-43 fragments corresponds to the pathological cleavage site identified in patients with the TAR DNA-binding protein-43 proteinopathies. Consistently, epigallocatechin gallate constrains prion-like interactions, attenuating pathological-like degradation. Thus, the native folding of TAR DNA-binding protein-43 C terminus acts as a guardian of pathogenesis, which is directly associated with loss-of-function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473010     DOI: 10.1038/ncomms1766

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  49 in total

1.  Stress granule assembly is mediated by prion-like aggregation of TIA-1.

Authors:  Natalie Gilks; Nancy Kedersha; Maranatha Ayodele; Lily Shen; Georg Stoecklin; Laura M Dember; Paul Anderson
Journal:  Mol Biol Cell       Date:  2004-09-15       Impact factor: 4.138

2.  Conformational variations in an infectious protein determine prion strain differences.

Authors:  Motomasa Tanaka; Peter Chien; Nariman Naber; Roger Cooke; Jonathan S Weissman
Journal:  Nature       Date:  2004-03-18       Impact factor: 49.962

3.  Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping.

Authors:  Martin Fenger-Grøn; Christy Fillman; Bodil Norrild; Jens Lykke-Andersen
Journal:  Mol Cell       Date:  2005-12-22       Impact factor: 17.970

4.  Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.

Authors:  Dagmar E Ehrnhoefer; Martin Duennwald; Phoebe Markovic; Jennifer L Wacker; Sabine Engemann; Margaret Roark; Justin Legleiter; J Lawrence Marsh; Leslie M Thompson; Susan Lindquist; Paul J Muchowski; Erich E Wanker
Journal:  Hum Mol Genet       Date:  2006-08-07       Impact factor: 6.150

5.  Dynamic interaction between P-bodies and transport ribonucleoprotein particles in dendrites of mature hippocampal neurons.

Authors:  Manuel Zeitelhofer; Daniela Karra; Paolo Macchi; Marco Tolino; Sabine Thomas; Martina Schwarz; Michael Kiebler; Ralf Dahm
Journal:  J Neurosci       Date:  2008-07-23       Impact factor: 6.167

6.  TDP-43: an emerging new player in neurodegenerative diseases.

Authors:  I-Fan Wang; Lien-Szu Wu; C-K James Shen
Journal:  Trends Mol Med       Date:  2008-10-15       Impact factor: 11.951

7.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

8.  Normal host prion protein necessary for scrapie-induced neurotoxicity.

Authors:  S Brandner; S Isenmann; A Raeber; M Fischer; A Sailer; Y Kobayashi; S Marino; C Weissmann; A Aguzzi
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

9.  Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Authors:  E Buratti; F E Baralle
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

10.  Transcription-dependent redistribution of the large subunit of RNA polymerase II to discrete nuclear domains.

Authors:  D B Bregman; L Du; S van der Zee; S L Warren
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  31 in total

1.  A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.

Authors:  Justin D Boyd; Peter Lee; Marisa S Feiler; Nava Zauur; Min Liu; John Concannon; Atsushi Ebata; Benjamin Wolozin; Marcie A Glicksman
Journal:  J Biomol Screen       Date:  2013-09-09

2.  Self-assembled FUS binds active chromatin and regulates gene transcription.

Authors:  Liuqing Yang; Jozsef Gal; Jing Chen; Haining Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

3.  Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease.

Authors:  Ian Diner; Chadwick M Hales; Isaac Bishof; Lake Rabenold; Duc M Duong; Hong Yi; Oskar Laur; Marla Gearing; Juan Troncoso; Madhav Thambisetty; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  J Biol Chem       Date:  2014-10-29       Impact factor: 5.157

Review 4.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

5.  RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.

Authors:  Isaac Bishof; Eric B Dammer; Duc M Duong; Sean R Kundinger; Marla Gearing; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  J Biol Chem       Date:  2018-05-25       Impact factor: 5.157

6.  Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones.

Authors:  Maria Udan-Johns; Rocio Bengoechea; Shaughn Bell; Jieya Shao; Marc I Diamond; Heather L True; Conrad C Weihl; Robert H Baloh
Journal:  Hum Mol Genet       Date:  2013-08-19       Impact factor: 6.150

7.  Myofibrillar disruption and RNA-binding protein aggregation in a mouse model of limb-girdle muscular dystrophy 1D.

Authors:  Rocio Bengoechea; Sara K Pittman; Elizabeth P Tuck; Heather L True; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2015-09-11       Impact factor: 6.150

8.  Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43.

Authors:  Carola Stribl; Aladin Samara; Dietrich Trümbach; Regina Peis; Manuela Neumann; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabě de Angelis; Birgit Rathkolb; Eckhard Wolf; Johannes Beckers; Marion Horsch; Frauke Neff; Elisabeth Kremmer; Sebastian Koob; Andreas S Reichert; Wolfgang Hans; Jan Rozman; Martin Klingenspor; Michaela Aichler; Axel Karl Walch; Lore Becker; Thomas Klopstock; Lisa Glasl; Sabine M Hölter; Wolfgang Wurst; Thomas Floss
Journal:  J Biol Chem       Date:  2014-02-10       Impact factor: 5.157

9.  UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination.

Authors:  Friederike Hans; Fabienne C Fiesel; Jennifer C Strong; Sandra Jäckel; Tobias M Rasse; Sven Geisler; Wolfdieter Springer; Jörg B Schulz; Aaron Voigt; Philipp J Kahle
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

10.  Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.

Authors:  Kaitlin Weskamp; Elizabeth M Tank; Roberto Miguez; Jonathon P McBride; Nicolás B Gómez; Matthew White; Ziqiang Lin; Carmen Moreno Gonzalez; Andrea Serio; Jemeen Sreedharan; Sami J Barmada
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.